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Microsoft Excel. The model compares the cost-effectiveness of
standard diagnostics with the one of ILR-enhanced diagnostic
pathways. Number of positive diagnoses was used as the
outcome measure. The number of diagnostic tests per patient and
the yield of each test were found in published clinical literature.
Cost data were taken from Dutch national sources. Sensitivity
analyses were conducted using Monte Carlo Simulation.
RESULTS: Literature and sensitivity analyses clearly show that
the ILR-based pathway has a signiﬁcantly higher capacity of
providing a correct diagnosis (33.7% vs. 4.1%) within the same
timeframe. The cost per diagnosis in the ILR-based pathway was
slightly higher than the cost per diagnosis of more conventional
care (approximately €1200 more needed per diagnosis with
ILRs). CONCLUSIONS: ILRs can be considered an established,
safe and efﬁcient addition to syncope diagnostics. They provide
physicians with excellent diagnostic yield, enabling timely and
correct treatment of patients whose condition could remain undi-
agnosed. Cost per diagnosis demonstrates the cost-effectiveness
of their use. Potentially, ILRs can also reduce time-to-diagnosis
and operational expenditure of the hospital. Should that be the
case, ILRs can be even more cost-effective while enabling more
patients to get life-saving treatment faster.
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OBJECTIVES: The IDEAL trial (Incremental Decrease in End
Points through Aggressive Lipid Lowering) was an open label,
blinded endpoint evaluation of 8888 patients with history of
acute myocardial infarction (MI) who were randomized to ator-
vastatin 80 mg or simvastatin 20–40 mg. The median follow-up
was 4.8 years. Major coronary events (coronary death, hospital-
ization for MI, or resuscitated cardiac arrest) were reduced by
11%, (hazard ratio [HR], 0.89; 95% conﬁdence interval [CI],
0.78, 1.01; P = 0.07). There was a 16% relative risk reduction in
all cardiovascular events (HR 0.84, 95% CI: 0.76 to 0.91). The
objective of the study was to asses the cost-effectiveness ratio of
atorvastatin 80 mg versus simvastatin 20–40 mg among patients
with history of coronary heart disease (CHD) in Spain taking
into account all CV events. METHODS: A within trial pharma-
coeconomic analysis was developed to estimate cost per event
avoided. Direct (hospitalization, drugs) and indirect costs (lost
production due to work absence) were included in the model. To
estimate the cost of these hospitalizations, drug reimbursement
group (DRG) was used. Effectiveness was estimated as the
number of events in both arms. RESULTS: After 4.8 years,
treatment with intensive atorvastatin could avoid 1 in 6 CV
events compared with moderate simvastatin therapy among
patients with CHD. Despite atorvastatin having a higher drug
cost, this was offset by lower cost of reduced hospitalizations and
work days lost for patients receiving atorvastatin treatment.
Using Spanish costs the incremental cost for atorvastatin to avoid
an event was €15,168. CONCLUSIONS: In a cohort of 8888
Spanish patients with CHD one cardiovascular event could be
prevented for cost of €1520 euros/patient over 4.8 years. Based
on these results, it appears that even in a low cost generic market,
high dose atorvastatin is a good option compared to standard
therapy with simvastatin.
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OBJECTIVES: The timely diagnosis of deep venous thrombosis
(DVT) is critical because this disorder can be life threatening.
However, referring all patients suspected of DVT for ultrasound
(US) testing is inefﬁcient since 80 to 90%of those referred have no
DVT. Therefore, we investigated the cost-effectiveness of a diag-
nostic strategy based on a point of care d-dimer test combined
with a clinical decision rule that was documented to be safe in
primary care (AMUSE study). METHODS: A model based cost-
effectiveness analysis was conducted in conjunction with a recent
multi centre prospective diagnostic study (AMUSE, N = 1002). A
Markov model with a ﬁve year time horizon was used to compare
the AMUSE strategy to two hospital based strategies: ultrasound
for all and a hospital decision rule. Probabilities were derived from
AMUSE and the literature. Societal costs and health state utilities
were used. One way and probabilistic sensitivity analyses were
conducted. Cost-effectiveness acceptability curves were con-
structed. RESULTS: The AMUSE strategy has both slightly lower
costs and less quality adjusted life years (QALYs) than both
hospital based strategies. The ultrasound for all strategy has the
highest costs andQALYs, but is not cost-effective as compared the
hospital decision rule strategy. The AMUSE strategy compared to
the hospital decision rule strategy resulted in a mean saving
of €138, and a mean QALY loss of 0.002. The incremental
cost-effectiveness ratio is €56,436 per QALY lost. The cost-
effectiveness acceptability curves show that the AMUSE strategy
has the highest probability of being cost-effective, even exceeding
ceiling ratios of €80,000 per QALY. CONCLUSIONS: The
AMUSE strategy to exclude DVT in primary care is not only safe,
but also has the highest probability of being cost-effective as
compared to hospital based strategies to diagnose DVT.
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OBJECTIVES: Hypertension and dyslipidemia are highly preva-
lent, often concurrent and act independently, as well as together,
to increase the risk of cardiovascular disease (CVD). This study
sought to investigate the cost-effectiveness of a single-pill com-
bination of amlodipine/atorvastatin (SPAA) for the primary pre-
vention of CVD (comprising coronary heart disease and ischemic
stroke) in Korea. METHODS: A Markov model was developed
with four health states: ‘Alive without CVD’, ‘Alive with CVD’,
‘Dead from CVD’ and ‘Dead from non-CVD causes’, The model
cohort used comprised 171 Korean adults aged 55 years from
the 2005 Korea National Health and Nutritional Examination
Survey (KNHANES) who were CVD-free but met current
Korean criteria for treatment with SPAA. Follow-up was simu-
lated for 40 years. Cardiovascular risk was estimated for each
subject individually using a published, multivariable, Asian-
speciﬁc equation. With subsequent cycles, the cardiovascular
risk proﬁle of each subject was updated. Data regarding the
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